53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- PMID: 20453858
- PMCID: PMC2912507
- DOI: 10.1038/nsmb.1831
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Abstract
Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a consequence of impaired recombinatorial DNA repair. Here we identify p53-binding protein 1 (53BP1) as an essential factor for sustaining the growth arrest induced by Brca1 deletion. Depletion of 53BP1 abrogates the ATM-dependent checkpoint response and G2 cell-cycle arrest triggered by the accumulation of DNA breaks in Brca1-deleted cells. This effect of 53BP1 is specific to BRCA1 function, as 53BP1 depletion did not alleviate proliferation arrest or checkpoint responses in Brca2-deleted cells. Notably, loss of 53BP1 partially restores the homologous-recombination defect of Brca1-deleted cells and reverts their hypersensitivity to DNA-damaging agents. We find reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of our findings.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0001.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0003.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0004.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0004.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0006.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0006.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2912507/bin/ukmss-31553-f0008.gif)
Comment on
-
Loss of 53BP1 is a gain for BRCA1 mutant cells.Cancer Cell. 2010 May 18;17(5):423-5. doi: 10.1016/j.ccr.2010.04.021. Cancer Cell. 2010. PMID: 20478525
Similar articles
-
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.Anticancer Res. 2023 Mar;43(3):967-981. doi: 10.21873/anticanres.16241. Anticancer Res. 2023. PMID: 36854505 Review.
-
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.J Cell Biol. 2013 Jan 21;200(2):187-202. doi: 10.1083/jcb.201204053. J Cell Biol. 2013. PMID: 23337117 Free PMC article.
-
53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12. Gynecol Oncol. 2013. PMID: 23246380 Free PMC article.
-
RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1.J Biol Chem. 2012 Nov 23;287(48):40618-28. doi: 10.1074/jbc.M112.410951. Epub 2012 Oct 10. J Biol Chem. 2012. PMID: 23055523 Free PMC article.
-
Therapeutic exploitation of tumor cell defects in homologous recombination.Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review.
Cited by
-
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.Nat Commun. 2024 May 24;15(1):4430. doi: 10.1038/s41467-024-48715-1. Nat Commun. 2024. PMID: 38789420 Free PMC article.
-
The chromatin-associated 53BP1 ortholog, HSR-9, regulates recombinational repair and X chromosome segregation in the Caenorhabditis elegans germ line.bioRxiv [Preprint]. 2024 Apr 15:2024.04.12.589267. doi: 10.1101/2024.04.12.589267. bioRxiv. 2024. Update in: Genetics. 2024 Jun 17:iyae102. doi: 10.1093/genetics/iyae102. PMID: 38659880 Free PMC article. Updated. Preprint.
-
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.Cancers (Basel). 2024 Feb 10;16(4):741. doi: 10.3390/cancers16040741. Cancers (Basel). 2024. PMID: 38398132 Free PMC article.
-
DNA Double Strand Break and Response Fluorescent Assays: Choices and Interpretation.Int J Mol Sci. 2024 Feb 13;25(4):2227. doi: 10.3390/ijms25042227. Int J Mol Sci. 2024. PMID: 38396904 Free PMC article. Review.
-
Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.Genes Dev. 2024 Feb 13;38(1-2):46-69. doi: 10.1101/gad.351408.123. Genes Dev. 2024. PMID: 38286657 Free PMC article.
References
-
- Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–182. - PubMed
-
- Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864–5874. - PubMed
-
- Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 2006;34:633–645. - PubMed
-
- Collins N, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10:1673–1675. - PubMed
-
- Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet. 1992;2:128–131. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous